Related Experiment Video

Updated: May 24, 2026

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

Cerebrovascular lesions in patients with frontotemporal lobar degeneration: a neuropathological study

Jacques L De Reuck1, V Deramecourt, C Cordonnier

  • 1UDSL, EA 1046, Université Lille Nord de France, Lille, France. dereuck.j@gmail.com

Neuro-Degenerative Diseases
|March 2, 2012
PubMed

Insights

Cerebrovascular pathology does not significantly impact frontotemporal lobar degeneration (FTLD). White matter changes were more common in FTLD, but not indicative of vascular disease progression.

Area of Science:

  • Neurology
  • Neuroscience
  • Pathology

Background:

  • Cerebrovascular lesions are common in Alzheimer's disease, with some linked to the disease's severity.
  • The role of cerebrovascular pathology in other neurodegenerative diseases like FTLD is less understood.
  • Investigating cerebrovascular impact in FTLD is crucial for understanding disease mechanisms.

Purpose of the Study:

  • To determine the impact of cerebrovascular pathology on the progression of frontotemporal lobar degeneration (FTLD).
  • To compare the prevalence and severity of small ischaemic and haemorrhagic lesions in FTLD brains versus controls.
  • To assess the association of vascular risk factors and antithrombotic agent use with cerebrovascular lesions in FTLD.

Main Methods:

  • Autopsy-proven FTLD brains (n=22) were compared to age-matched control brains (n=15).
  • Prevalence and severity of small ischaemic and haemorrhagic lesions were assessed.
  • Vascular risk factors and antithrombotic medication use were recorded.

Main Results:

  • FTLD patients exhibited heterogeneity in disease onset, duration, genetics, and pathology.
  • Cerebrovascular risk factors and lesions were infrequent in FTLD and controls, with no significant differences.
  • White matter changes were more prevalent (p=0.04) and trended towards greater severity (p=0.08) in FTLD brains.

Conclusions:

  • Cerebrovascular pathology does not appear to contribute to the disease process in FTLD.
  • Isolated white matter changes in FTLD should not be interpreted as a sign of vascular disease.
  • Further research may clarify the specific role of white matter changes in FTLD pathogenesis.
Abstract

More Related Videos

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions07:30

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions

Published on: April 23, 2021

Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly12:50

Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly

Published on: April 14, 2014

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Hemorrhagic Stroke ll: Pathophysiology01:29

Hemorrhagic Stroke ll: Pathophysiology

A hemorrhagic stroke develops when a cerebral blood vessel ruptures, allowing blood to escape into the surrounding brain tissue, as in intracerebral hemorrhage (ICH), or into the subarachnoid space, as in subarachnoid hemorrhage (SAH). Because the skull is a rigid compartment, the sudden presence of extravascular blood rapidly increases intracranial pressure and compresses adjacent neural structures, leading to immediate tissue injury and impaired cerebral perfusion.Mass Effect and Primary...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...